Back to Agenda
Drug Repurposing: Opportunities & Challenges
Session Chair(s)
Tamara Di Carlantonio, MA
Regulatory Policy Lead
Roche, Switzerland
Drug repurposing is regarded as a potential solution to treatment gaps and increasing healthcare costs, especially after COVID. However, this complex topic grants deeper discussion and a collaborative, multi-stakeholder approach.
Learning Objective : • Uncover the different aspects that come to play in drug repurposing: (including but not limited to) scientific, regulatory, patient access, healthcare systems, commercial • Articulate areas where repurposing presents opportunities • Describe current and potential challenges • Discuss how to tackle challenges in order to realize opportunities
Speaker(s)
EMA Repurposing Pilot
Alberto Ganan Jimenez, PhD
European Medicines Agency, Netherlands
Head of Committees and Quality Assurance
Donald Lo, PhD
EATRIS, Netherlands
Director of Medicines Development
Targeted Therapy in PIK3CA-Related Overgrowth Syndrome
Guillaume Canaud
Neckar Enfants Malades Hospital, France
Chief of the Overgrowth Syndromes and Vascular anomalies Unit
Drug Repurposing: How to Proceed?
François Houyez
European Organisation for Rare Diseases (EURORDIS), France
Treatment Information and Access Director, Health Policy Advisor
Panelist
Solange Corriol-Rohou, DrMed, MD, PhD
AstraZeneca , France
Senior Director, Global Regulatory Affairs & Policy, R&D, Europe
Panelist
Sini Eskola, MPharm, MS, MSc
EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium
Director Regulatory Strategy
Have an account?